鹿哈合剂防治绝经后骨质疏松症临床研究  

Clinical Study on the Prevention and Treatment of Postmenopausal Osteoporosis with Luha Heji(鹿哈合剂)

作　　者：王丹辉[1] 王丹彤[1] 尉凤娟 赵洪峰[1] 杨震[1] 金影[1] 刘震坤[1] 王照辉[1] 

机构地区：[1]吉林省中医药科学院,吉林长春130021

出　　处：《风湿病与关节炎》2016年第12期12-14,48,共4页Rheumatism and Arthritis

基　　金：吉林省科技攻关计划(20150204057YY)

摘　　要：目的:观察鹿哈合剂对绝经后骨质疏松症的临床疗效。方法:将120例绝经后骨质疏松症患者随机分为治疗组和对照组,每组60例。治疗组给予鹿哈合剂治疗,对照组给予仙灵骨葆胶囊治疗。2组疗程均为6个月。观察2组治疗前后临床症状、体征评分及骨密度、骨代谢指标变化情况。结果:治疗后,2组临床症状、体征积分均较治疗前降低(P<0.01),治疗组降低更明显(P<0.01);2组骨密度与治疗前比较,差异无统计学意义(P>0.05);2组血清雌二醇含量较治疗前升高,治疗组优于对照组,差异有统计学意义(P<0.01);2组血清骨碱性磷酸酶、Ⅰ型胶原交联羧基末端肽含量较治疗前降低,治疗组优于对照组,差异有统计学意义(P<0.01)。结论:鹿哈合剂能够改善绝经后骨质疏松症患者的临床症状,提高患者雌激素水平,降低骨碱性磷酸酶、Ⅰ型胶原交联羧基末端肽水平,对绝经后骨质疏松症有防治作用。Objective：To observe the clinical effect of Luha Heji （ 鹿哈合剂 ） on postmenopausal osteoporosis.Methods：One hundred and twenty cases of postmenopausal osteoporosis were randomly divided into a treatment group and a control group,60 cases in each.The treatment group was treated with Luha Heji,while the control group with Xianlinggubao Jiaonang （ 仙灵骨葆胶囊 ） .After six-month treatment,the two groups were observed on the aspects of changes of clinical symptoms and sign scores and indexes of bone mineral density and bone metabolism.Results：After treatment,the sign scores of the two groups were significantly lower than those before treatment （P 〈 0.01 ） ,with the treatment group decreasing more significantly （P 〈 0.01 ） .There was no significant difference in bone mineral density between the two groups after treatment （ P 〉 0.05 ） .The serum estradiol levels in the two groups were higher than before treatment,and the treatment group was better than the control group,the difference being statistically significant （ P 〈 0.01 ） .The contents of serum bone alkaline phosphatase and type [ collagen cross-linked carboxyl terminal peptide of the two groups were lower than before treatment,and the treatment group was better than the control group,the difference being statistically significant （P 〈 0.01 ） .Conclusion：Luha Heji can improve clinical symptoms of osteoporosis patients,increase their estrogen levels and decrease the levels of bone alkaline phosphatase and type I collagen cross-linked carboxy terminal peptide,available for the prevention and treatment of postmenopausal osteoporosis.

关 键 词：绝经后骨质疏松症 鹿哈合剂 骨密度 骨代谢标志物 

分 类 号：R580[医药卫生—内分泌]